Primary Mediastinal Large B Cell Lymphoma Clinical Trial
Official title:
A Phase II Study on the Safety and Efficacy of Zanubrutinib Combined With Tislelizumab in the Treatment of Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma and Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
The study is to investigate the safety and efficacy of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.
R-CHOP regimen is the first-line therapy in DLBCL which greatly improved the efficacy of diffuse large B-cell lymphoma (DLBCL) and achieved good long-term survival. However, among DLBCL patients treated with R-CHOP, EBV+ had a lower 5-year OS than EBV- patients (65% vs 82%). For primary mediastinal large B-cell lymphoma (PMBCL), although the initial treatment has a better prognosis than DLBCL, there are still 10% to 30% of PMBCL patients with primary refractory or relapsed disease, and the prognosis is poor. Zanubrutinib combined with Tislelizumab has been proved efficient in relapsed or refractory NHLs, with ORR rate 37%, CR rate of 16.7%. This phase II, prospective, open-label, single-arm study will evaluate the efficacy and safety of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04545762 -
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
Recruiting |
NCT05934448 -
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
|
Phase 2 | |
Recruiting |
NCT05326243 -
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT04323657 -
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT04844086 -
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04067414 -
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT06412068 -
A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment
|
Phase 2 | |
Active, not recruiting |
NCT04464200 -
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
|
Phase 1 | |
Recruiting |
NCT05653271 -
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
|
Phase 1 | |
Enrolling by invitation |
NCT04488354 -
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
|
Phase 1 | |
Recruiting |
NCT05377307 -
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
|
||
Withdrawn |
NCT04503538 -
Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity
|
N/A | |
Active, not recruiting |
NCT04542824 -
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04450069 -
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
|
Phase 1 | |
Recruiting |
NCT05544019 -
Study of SGR-1505 in Mature B-Cell Neoplasms
|
Phase 1 | |
Active, not recruiting |
NCT01516567 -
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
|
Phase 2 |